Global Bioenergies SA
PAR:ALGBE
Intrinsic Value
Global Bioenergies SA develops industrial processes to convert renewable sources into isobutene. [ Read More ]
The intrinsic value of one
ALGBE
stock under the Base Case scenario is
0.76
EUR.
Compared to the current market price of 1.85 EUR,
Global Bioenergies SA
is
Overvalued by 59%.
ALGBE's market price has consistently been higher than its intrinsic value.This persistent overvaluation suggests the market may be overly optimistic about
ALGBE or that its price is influenced by factors unrelated to fundamentals.
Global Bioenergies SA's market capitalization is 33.5m EUR.
ALGBE stock price is 1.85 EUR.
ALGBE stock (0.76 EUR) is 59% less than its price (1.85 EUR).
ALGBE. Open DCF Valuation
ALGBE stock (0.76 EUR) is 59% less than its price (1.85 EUR). Open Relative Valuation
ALGBE has upside potential of 95% compared to the average analyst price target.
Open Wall St Estimates
ALGBE's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -134% to -151%, and is approaching profitability.
ALGBE's Revenue has grown by an exceptional 366% over the past 12 months.
ALGBE's ROE (Return on Equity) has significantly increased in the last 3 years from -161% to -96%, and is approaching profitability.
ALGBE has negative Operating Income for the last twelve months.
ALGBE has negative Net Income for the last twelve months.
ALGBE's ROE (Return on Equity) for the past 12 months is negative and is equal to -96%.
ALGBE's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -151%.
ALGBE's long-term assets (18m EUR) exceed its long-term liabilties (8m EUR).
ALGBE has negative Gross Profit for the last twelve months.
ALGBE's D/E (Debt to Equity) is very low and is equal to 0.36.
ALGBE has negative Free Cash Flow for the last twelve months.
ALGBE's Revenue has been growing by an exceptional 271% per year for the last 3 years.
ALGBE has negative Net Debt. This means that the company has more cash and short-term investments (12m EUR) than debt (4m EUR).
ALGBE's short-term assets (15m EUR) exceed its short-term liabilties (4m EUR).
ALGBE has negative three-year average ROE (Return on Equity): -155%. The company is not efficient at transforming stockholders' equity into net income.
ALGBE has negative three-year average ROIC (Return on Invested Capital): -150%. The company is not efficient at using invested capital to generate operating income.
ALGBE's Altman Z-Score is very low and is equal to 0.33.
Valuation Backtest
Global Bioenergies SA
Run backtest to discover the historical profit from buying and selling
ALGBE
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Global Bioenergies SA
Balance Sheet Decomposition
Global Bioenergies SA
| Current Assets | 15m |
| Cash & Short-Term Investments | 11.8m |
| Receivables | 2.2m |
| Other Current Assets | 947.3k |
| Non-Current Assets | 3.2m |
| Long-Term Investments | 341k |
| PP&E | 2.5m |
| Intangibles | 327.3k |
| Current Liabilities | 4.1m |
| Accounts Payable | 2.4m |
| Accrued Liabilities | 222.2k |
| Other Current Liabilities | 1.5m |
| Non-Current Liabilities | 3.8m |
| Long-Term Debt | 3.7m |
| Other Non-Current Liabilities | 53.4k |
Earnings Waterfall
Global Bioenergies SA
|
Revenue
|
3.2m
EUR
|
|
Cost of Revenue
|
-8.2m
EUR
|
|
Gross Profit
|
-5m
EUR
|
|
Operating Expenses
|
-4.5m
EUR
|
|
Operating Income
|
-9.5m
EUR
|
|
Other Expenses
|
816.5k
EUR
|
|
Net Income
|
-8.7m
EUR
|
Free Cash Flow Analysis
Global Bioenergies SA
ALGBE Profitability Score
Profitability Due Diligence
Global Bioenergies SA's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
Score
Global Bioenergies SA's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
ALGBE Solvency Score
Solvency Due Diligence
Global Bioenergies SA's solvency score is 60/100. The higher the solvency score, the more solvent the company is.
Score
Global Bioenergies SA's solvency score is 60/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ALGBE Price Targets Summary
Global Bioenergies SA
According to Wall Street analysts, the average 1-year price target for
ALGBE
is 3.6 EUR
with a low forecast of 2.83 EUR and a high forecast of 4.2 EUR.
Shareholder Return
ALGBE Price
Global Bioenergies SA
| Average Annual Return | 0.16% |
| Standard Deviation of Annual Returns | 57.17% |
| Max Drawdown | -81% |
| Market Capitalization | 33.5m EUR |
| Shares Outstanding | 18 091 600 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Global Bioenergies SA
Country
Industry
Market Cap
Dividend Yield
Description
Global Bioenergies SA develops industrial processes to convert renewable sources into isobutene. The company is headquartered in Evry, Ile-De-France. The company went IPO on 2011-06-09. Isobutene, a hydrocarbon, can be converted into fuels such as isooctane, as well as into various materials (synthetic rubber, organic glass, plastics). The process developed by Global Bioenergies SA is based on the design of an artificial metabolic pathway comprising several enzymes catalyzing reactions not observed in nature. Six patent applications have been filed by the Company. The first two applications covering the key steps of the bio-production of isobutene and other olefins have already been published. The company distributes butane and propane containing bio-isobutene, in a e partnership with Global Bioenergies. The company operates through Syngip.
Contact
IPO
Employees
Officers
The intrinsic value of one
ALGBE
stock under the Base Case scenario is
0.76
EUR.
Compared to the current market price of 1.85 EUR,
Global Bioenergies SA
is
Overvalued by 59%.
You don't have any saved screeners yet
